Product Watch
Retina recap: EMA and US FDA approvals, March 2025
Regulatory agencies issued approvals for new treatments and expanded uses of existing therapies in the retina space
Higher Molar Dose and Its Translation into Clinical Practice
Opthea discontinues COAST and ShORe sozinibercept combination therapy trials
Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration
French OPHTAMYOP study reveals trends in myopia control
How studies into myopia management can increase access to vision care
EMA grants positive CHMP opinion for low-dose atropine SYD-101 (Ryjunea, Sydnexis)
A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary endpoint for slowing paediatric myopia progression
New study investigates ocular involvement in multiple myeloma
Hematologists and ophthalmologists could work together for earlier diagnoses, research findings indicate
